Vitiligo showdown: light therapy vs pill in new trial

NCT ID NCT07055529

Not yet recruiting Disease control Sponsor: Hayat Abad Medical Complex, Peshawar Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatments for generalized vitiligo: PUVA therapy (a light-based treatment) and the pill Tofacitinib. Researchers will enroll 64 adults with stable vitiligo covering more than 10% of their body. The goal is to see which treatment works better and is safer for restoring skin color over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Psoralen combined with Ultraviolet A (PUVA) and Tofacitinib
What this could lead to: If successful, this could point toward a more effective treatment option for vitiligo, helping restore skin color in affected areas.
What could go wrong: This is a very early, small trial (64 people) that hasn't started yet. Results may not apply to everyone, and both treatments have risks like skin reactions or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates